Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Sitaram Harihar is active.

Publication


Featured researches published by Sitaram Harihar.


Journal of Biological Chemistry | 2008

Breast Cancer Metastasis Suppressor-1 Differentially Modulates Growth Factor Signaling

Kedar S. Vaidya; Sitaram Harihar; Pushkar A. Phadke; Lewis J. Stafford; Douglas R. Hurst; David G. Hicks; Graham Casey; Daryll B. DeWald; Danny R. Welch

That metastatic tumor cells grow in selective non-native environments suggests an ability to differentially respond to local microenvironments. BRMS1, like other metastasis suppressors, halts ectopic growth (metastasis) without blocking orthotopic tumor formation. BRMS1-expressing tumor cells reach secondary sites but do not colonize distant tissues, compelling the hypothesis that BRMS1 selectively restricts the ability of tumor cells to respond to exogenous regulators in different tissues. Here we report that BRMS1 expression in metastatic human breast cancer cells leads to a selective reduction in epidermal growth factor receptor expression and downstream (AKT) signaling. Signaling through another receptor tyrosine kinase, hepatocyte growth factor receptor (c-Met), remains unaltered despite reduced levels of the signaling intermediate phosphatidylinositol (4,5)-bisphosphate. Interestingly, reduced downstream calcium signaling is observed following treatment with platelet-derived growth factor, consistent with decreased phosphatidylinositol (4,5)-bisphosphate. However, platelet-derived growth factor receptor expression is unaltered. Thus, BRMS1 differentially attenuates cellular responses to mitogenic signals, not only dependent upon the specific signal received, but at varying steps within the same signaling cascade. Specific modulation of signaling responses received from the microenvironment may ultimately dictate which environments are permissive/restrictive for tumor cell growth and provide insights into the biology underlying metastasis.


Cancer Letters | 2010

BRMS1 expression alters the ultrastructural, biomechanical and biochemical properties of MDA-MB-435 human breast carcinoma cells: An AFM and Raman microspectroscopy study

Yangzhe Wu; Gerald D. McEwen; Sitaram Harihar; Sherry M. Baker; Daryll B. DeWald; Anhong Zhou

Restoring BReast cancer Metastasis Suppressor 1 (BRMS1) expression suppresses metastasis in MDA-MB-435 human breast carcinoma cells at ectopic sites without affecting tumor formation at orthotopic site in the body. BRMS1 expression induces many phenotypic alterations in 435 cells such as cell adhesion, cytoskeleton rearrangement, and the down regulation of epidermal growth factor receptor (EGFR) expression. In order to better understand the role of cellular biomechanics in breast cancer metastasis, the qualitative and quantitative detection of cellular biomechanics and biochemical composition is urgently needed. In the present work, using atomic force microscopy (AFM) and fluorescent microscopy we revealed that BRMS1 expression in 435 cells induced reorganization of F-actin and caused alteration in cytoarchitectures (cell topography and ultrastructure). Results from AFM observed increase in biomechanical properties which include cell adhesion, cellular spring constant, and Youngs modulus in 435/BRMS1 cells. Raman microspectroscopy showed weaker vibrational spectroscopic bands in 435/BRMS1 cells, implying decrease in concentration of cellular biochemical components in these cells. This was despite the similar spectral patterns observed between 435 and 435/BRMS1 cells. This work demonstrated the feasibility of applying AFM and Raman techniques for in situ measurements of the cellular biomechanics and biochemical components of breast carcinoma cells. It provides vital clues in understanding of the role of cellular biomechanics in cancer metastasis, and further the development of new techniques for early diagnosis of breast cancer.


Journal of Molecular Medicine | 2014

Metastasis suppressors in breast cancers: mechanistic insights and clinical potential

Christopher R. Bohl; Sitaram Harihar; Warren Lewis Denning; Rahul Sharma; Danny R. Welch

For the most part, normal epithelial cells do not disseminate to other parts of the body and proliferate, as do metastatic cells. Presumably, a class of molecules—termed metastasis suppressors—are involved in this homeostatic control. Metastasis suppressors are, by definition, cellular factors that, when re-expressed in metastatic cells, functionally inhibit metastasis without significantly inhibiting tumor growth. In this brief review, we catalog known metastasis suppressors, what is known about their mechanism(s) of action, and experimental and clinical associations to date.


Oncotarget | 2015

Crocetinic acid inhibits hedgehog signaling to inhibit pancreatic cancer stem cells

Parthasarathy Rangarajan; Dharmalingam Subramaniam; Santanu Paul; Deep Kwatra; Kanagaraj Palaniyandi; Shamima Islam; Sitaram Harihar; William G. Gutheil; Sandeep Putty; Rohan Pradhan; Subhash Padhye; Danny R. Welch; Shrikant Anant; Animesh Dhar

Pancreatic cancer is the fourth leading cause of cancer deaths in the US and no significant treatment is currently available. Here, we describe the effect of crocetinic acid, which we purified from commercial saffron compound crocetin using high performance liquid chromatography. Crocetinic acid inhibits proliferation of pancreatic cancer cell lines in a dose- and time-dependent manner. In addition, it induced apoptosis. Moreover, the compound significantly inhibited epidermal growth factor receptor and Akt phosphorylation. Furthermore, crocetinic acid decreased the number and size of the pancospheres in a dose-dependent manner, and suppressed the expression of the marker protein DCLK-1 (Doublecortin Calcium/Calmodulin-Dependent Kinase-1) suggesting that crocetinic acid targets cancer stem cells (CSC). To understand the mechanism of CSC inhibition, the signaling pathways affected by purified crocetinic acid were dissected. Sonic hedgehog (Shh) upon binding to its cognate receptor patched, allows smoothened to accumulate and activate Gli transcription factor. Crocetinic acid inhibited the expression of both Shh and smoothened. Finally, these data were confirmed in vivo where the compound at a dose of 0.5 mg/Kg bw suppressed growth of tumor xenografts. Collectively, these data suggest that purified crocetinic acid inhibits pancreatic CSC, thereby inhibiting pancreatic tumorigenesis.


Analytica Chimica Acta | 2014

Imaging of epidermal growth factor receptor on single breast cancer cells using surface-enhanced Raman spectroscopy

Lifu Xiao; Sitaram Harihar; Danny R. Welch; Anhong Zhou

Epidermal growth factor receptor (EGFR) is widely used as a biomarker for pathological grading and therapeutic targeting of human cancers. This study investigates expression, spatial distribution as well as the endocytosis of EGFR in single breast cancer cells using surface-enhanced Raman spectroscopy (SERS). By incubating anti-EGFR antibody conjugated SERS nanoprobes with an EGFR-over-expressing cancer cell line, A431, EGFR localization was measured over time and found to be located primarily at the cell surface. To further validate the constructed SERS probes, we applied this SERS probes to detect the EGFR expression on breast cancer cells (MDA-MB-435, MDA-MB-231) and their counterpart cell lines in which EGFR expression was down-regulated by breast cancer metastasis suppressor 1 (BRMS1). The results showed that SERS method not only confirms immunoblot data measuring EGFR levels, but also adds new insights regarding EGFR localization and internalization in living cells which is impossible in immunoblot method. Thus, SERS provides a powerful new tool to measure biomarkers in living cancer cells.


ChemMedChem | 2007

Synthesis and Biological Activity of Metabolically Stabilized Cyclopentyl Trisphosphate Analogues of D‐myo‐Ins(1,4,5)P3

Liuyin Zhang; Wei Huang; Akihiko Tanimura; Takao Morita; Sitaram Harihar; Daryll B. DeWald; Glenn D. Prestwich

We describe the synthesis of four novel metabolically stabilized analogues of Ins(1,4,5)P3 based on the known cyclopentane pentaol tris(phosphate) 2: tris(phosphorothioate) 3, tris(methylenephosphate) 4, tris(sulfonamide) 5, and tris(sulfate) 6. Of these analogues, only the tris(phosphorothioate) 3 and parent tris(phosphate) 2 bound to the type I InsP3R construct. In addition, both the tris(phosphorothioate) 3 and parent tris(phosphate) 2 elicited calcium release in MDA MB‐435 breast cancer cells. The Ins(1,4,5)P3 agonist activities of these two compounds can be rationalized on the basis of computational docking of the ligands to the binding domain of the type I InsP3R.


PLOS ONE | 2014

Furin Is the Major Proprotein Convertase Required for KISS1-to-Kisspeptin Processing

Sitaram Harihar; Keke M. Pounds; Tomoo Iwakuma; Nabil G. Seidah; Danny R. Welch

KISS1 is a broadly functional secreted proprotein that is then processed into small peptides, termed kisspeptins (KP). Since sequence analysis showed cleavage at KR or RR dibasic sites of the nascent protein, it was hypothesized that enzyme(s) belonging to the proprotein convertase family of proteases process KISS1 to generate KP. To this end, cell lines over-expressing KISS1 were treated with the proprotein convertase inhibitors, Dec-RVKR-CMK and α1-PDX, and KISS1 processing was completely inhibited. To identify the specific enzyme(s) responsible for KISS1 processing, mRNA expression was systematically analyzed for six proprotein convertases found in secretory pathways. Consistent expression of the three proteases – furin, PCSK5 and PCSK7 – were potentially implicated in KISS1 processing. However, shRNA-mediated knockdown of furin – but not PCSK5 or PCSK7 – blocked KISS1 processing. Thus, furin appears to be the essential enzyme for the generation of kisspeptins.


Analytical Methods | 2015

In vitro biophysical, microspectroscopic and cytotoxic evaluation of metastatic and non-metastatic cancer cells in responses to anti-cancer drug.

Qifei Li; Lifu Xiao; Sitaram Harihar; Danny R. Welch; Elizabeth Vargis; Anhong Zhou

The Breast Cancer Metastasis Suppressor 1 (BRMS1) is a nucleo-cytoplasmic protein that suppresses cancer metastasis without affecting the growth of the primary tumor. Previous work has shown that it decreases the expression of protein mediators involved in chemoresistance. This study measured the biomechanical and biochemical changes in BRMS1 expression and the responses of BRMS1 to drug treatments on cancer cells in vitro. The results show that BRMS1 expression affects biomechanical properties by decreasing the Youngs modulus and adhesion force of breast cancer cells after doxorubicin (DOX) exposure. Raman spectral bands corresponding to DNA/RNA, lipids and proteins were similar for all cells after DOX treatment. The expression of cytokines were similar for cancer cells after DOX exposure, although BRMS1 expression had different effects on the secretion of cytokines for breast cancer cells. The absence of significant changes on apoptosis, reactive oxygen species (ROS) expression and cell viability after BRMS1 expression shows that BRMS1 has little effect on cellular chemoresistance. Analyzing cancer protein expression is critical in evaluating therapeutics. Our study may provide evidence of the benefit of metastatic suppressor expression before chemotherapy.


Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy | 2017

Gd2O3-doped silica @ Au nanoparticles for in vitro imaging cancer biomarkers using surface-enhanced Raman scattering

Lifu Xiao; Xiumei Tian; Sitaram Harihar; Qifei Li; Li Li; Danny R. Welch; Anhong Zhou

There has been an interest in developing multimodal approaches to combine the advantages of individual imaging modalities, as well as to compensate for respective weaknesses. We previously reported a composite nano-system composed of gadolinium-doped mesoporous silica nanoparticle and gold nanoparticle (Gd-Au NPs) as an efficient MRI contrast agent for in vivo cancer imaging. However, MRI lacks sensitivity and is unsuitable for in vitro cancer detection. Thus, here we performed a study to use the Gd-Au NPs for detection and imaging of a widely recognized human cancer biomarker, epidermal growth factor receptor (EGFR), in individual human cancer cells with surface-enhanced Raman scattering (SERS). The Gd-Au NPs were sequentially conjugated with a monoclonal antibody recognizing EGFR and a Raman reporter molecule, 4-meraptobenzoic acid (MBA), to generate a characteristic SERS signal at 1075cm-1. By spatially mapping the SERS intensity at 1075cm-1, cellular distribution of EGFR and its relocalization on the plasma membrane were measured in situ. In addition, the EGFR expression levels in three human cancer cell lines (S18, A431 and A549) were measured using this SERS probe, which were consistent with the comparable measurements using immunoblotting and immunofluorescence. Our SERS results show that functionalized Gd-Au NPs successfully targeted EGFR molecules in three human cancer cell lines and monitored changes in single cell EGFR distribution in situ, demonstrating its potential to study cell activity under physiological conditions. This SERS study, combined with our previous MRI study, suggests the Gd-Au nanocomposite is a promising candidate contrast agent for multimodal cancer imaging.


Cancer Research | 2014

Abstract 1990: Identification and biochemical characterization of HMP19, a tumor/metastasis suppressor in pancreatic cancer

Christopher R. Bohl; Hiroshi Kurahara; Shoji Natsugoe; Yuka Nishizono; Sitaram Harihar; Tomoo Iwakuma; Danny R. Welch

The overwhelming majority of pancreatic cancer is not diagnosed until the cancer has metastasized, which leads to an abysmal average life expectancy (3 to 6 months post-diagnosis). Earlier detection and more effective treatments have been hampered by inadequate understanding of the underlying molecular mechanisms controlling metastasis. Metastasis suppressors inhibit metastasis without blocking orthotopic tumor growth and represent powerful new targets and biomarkers. We hypothesize that metastasis suppressors are involved in controlling metastasis in pancreatic cancer. Using an unbiased genome wide shRNA screen, we identified HMP19 as a putative metastasis suppressor in pancreatic ductal adenocarcinoma (PDAC). Functional validation was carried out by manipulating expression in PDAC cell lines. Knockdown of HMP19 in S2-028 cells increased orthotopic tumor growth and liver metastasis, while over-expression in S2-007 cells slowed tumor growth and suppressed metastasis in xenographs. HMP19 expression inversely correlated with in vitro migration, colony formation, proliferation, and cyclin E1 expression. In clinical samples, HMP19 expression inversely correlated with tumor size, plexus invasion, liver metastasis, and patient survival (p Support: National Foundation for Cancer Research, Hall Family Foundation, Kansas Bioscience Authority, and CA134981 Citation Format: Christopher R. Bohl, Hiroshi Kurahara, Shoji Natsugoe, Yuka Nishizono, Sitaram Harihar, Tomoo Iwakuma, Danny R. Welch. Identification and biochemical characterization of HMP19, a tumor/metastasis suppressor in pancreatic cancer. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 1990. doi:10.1158/1538-7445.AM2014-1990

Collaboration


Dive into the Sitaram Harihar's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Lifu Xiao

Utah State University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Qifei Li

Utah State University

View shared research outputs
Researchain Logo
Decentralizing Knowledge